The purpose of this study was to develop a flow cytometric approach to the evaluation of marrow dysplasia in myelodysplastic syndromes (MDS). We first studied a cohort of 103 MDS patients as well as 46 pathological and healthy controls. Flow cytometry data were expressed as percentage of positive cells. Analysis of erythroid cells showed higher proportions of immature cells (Po0.001) and decreased levels of CD71 expression on nucleated red cells (P ¼ 0.02) in MDS. Analysis of myeloid cells showed lower proportions of CD10 þ and higher proportions of CD56 þ granulocytes (Po0.001), and increased ratios of immature to mature cells (P ¼ 0.007). Since no single immunophenotype could accurately differentiate MDS from other conditions, we used discriminant analysis for generating erythroid and myeloid classification functions using combinations of immunophenotypic parameters. These functions were prospectively validated in a testing cohort of 69 MDS patients and 46 pathological controls. A diagnosis of MDS was obtained in 60/69 cases (87%). No false-positive results were noticed among controls. Significant correlations between values of these functions and both degree of morphological dysplasia and the International Prognostic Scoring System were found. These findings indicate that flow cytometry evaluation of marrow dysplasia is feasible and may be useful in the work-up of individual MDS patients.
Introduction
Myelodysplastic syndromes (MDS) are abnormal proliferations of hematopoietic stem cells that retain their capacity to differentiate but do so in an inefficient manner, so that bone marrow (BM) and peripheral blood cells show various morphological abnormalities and the numbers of mature blood cells are variably reduced. 1, 2 These disorders are characterized clinically by BM failure, followed by a progressive impairment in the ability of myelodysplastic stem cells to differentiate and an increasing risk of evolution into acute myeloid leukemia (AML).
Since dysplasia is the pathologic hallmark and various chromosomal abnormalities may be found in these patients, the current diagnostic approach includes peripheral blood and BM morphology, BM histology, and cytogenetics. 3 In vitro cultures of hematopoietic progenitors can provide additional useful information for the diagnosis of MDS, since colony formation is poor or absent in most of these patients. 4 Thus, overt marrow dysplasia, clonal cytogenetic abnormality, and reduced in vitro progenitor cell growth allow a conclusive diagnosis of MDS. 1 This combination is, however, found in only some MDS patients, who tend to be those with more advanced disease. 5 In many instances, cytogenetics is not informative and BM cultures are not performed, so that the diagnosis of MDS is based entirely and exclusively on morphological criteria.
Flow cytometry immunophenotyping, a reliable method for quantitative and qualitative evaluation of hematopoietic cells, is playing an increasingly crucial role in the diagnosis and management of acute leukemias. 6 MDS patients have been found to have abnormal expression of several surface antigens, as indicated by either the intensity of fluorescence or the percentage of positive cells. 7 Findings of recent studies suggest that flow cytometry immunophenotyping might provide useful information in management of MDS patients. [8] [9] [10] [11] [12] The purpose of this study was to develop a flow-cytometric approach to the evaluation of erythroid and myeloid dysplasia in patients with MDS.
Materials and methods

Patients and controls
This study enrolled patients followed at the Division of Hematology, IRCCS Policlinico San Matteo and University of Pavia Medical School, Pavia, Italy. The procedures followed were in accordance with the Ethical standards of the institutional committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 1983. The cytological diagnosis of MDS was initially made according to the FAB criteria, 13 all cases were then reclassified according to the WHO classification. 3 Patients with RAEB-T were excluded from this study.
Morphological analysis of marrow specimens was performed by two or three independent cytologists, who were blinded to the cytometric data. A total of 500 BM nucleated cells per sample were assessed. The evaluation of the erythroid lineage was based on the detection of megaloblastic changes, nuclear lobulation, multinuclearity, and cytoplasmic granules/inclusions. In the myeloid lineage, the following abnormalities were considered: bizarre nuclear shape, hypo-or agranularity, nuclear/cytoplasmic asynchrony, and pseudo-Pelger anomaly. Micromegakaryocytes, small binucleated megakaryocytes, megakaryocytes with small round separated nuclei, and megathrombocytes were considered signs of megakaryocytic dysplasia.
The degree of erythroid or myeloid dysplasia was defined according to the following morphological scoring system: 0 (absence of dysplasia, 0-2% of abnormal cells), 1 (mild dysplasia, 3-9% of abnormal cells), 2 (moderate dysplasia, 10-29% of abnormal cells), and 3 (severe dysplasia, 30% or more abnormal cells).
Cytogenetic analysis was performed at diagnosis, using standard G-banding with trypsin-Giemsa staining, 14 and karyotypes were classified using the International System for Cytogenetic Nomenclature Criteria. 15 FISH studies were performed as described previously. 16, 17 The International Prognostic Scoring System (IPSS) was employed to define prognosis according to Greenberg et al. 18 This study involved two cohorts of patients and controls: (a) a 'learning cohort', whose investigations were aimed at defining discriminant immunophenotypic markers; (b) a 'testing cohort' on which we examined whether our discriminant markers were able to reproduce what we had found in the learning cohort.
19-21
Flow cytometry studies K3-EDTA BM aspirate specimens were collected and stained within 3 h using a whole-blood lysis technique (FACS lysing solution, Becton Dickinson, San José, CA, USA) and a panel of direct conjugated monoclonal antibodies (MoAb) according to standard procedures described previously.
Six-parameter, four-color flow cytometry was performed with a FACSCalibur flow cytometer (Becton Dickinson) equipped with a 15-nW argon laser (excitation at 488 nm). Daily instrument quality control, including fluorescence standardization, linearity assessment, and spectral compensation, were performed to ensure identical operation from day to day.
At least 50 000 events were acquired for each sample in linear mode for side scatter (SSC) and in log mode for fluorescent signals; isotype-matched negative controls were used in all assays. Data were collected and analyzed with CellQuest software (Becton Dickinson).
The MoAb panel employed was as follows: fluorescein isothiocyanate (FITC)-conjugated anti CD3, CD5, CD7, CD15, CD16, CD34, and CD71; phycoerythrin (PE)-conjugated anti CD4, CD8, CD10, CD13, CD19, CD33, CD34, CD56, and antiglycophorin A (GlyA); allophycocyanine (APC)-conjugated CD14, CD19 and CD45; Tri-Color (TC, PE-Cyanine5)-conjugated anti CD45. All MoAbs were purchased from Becton Dickinson except CD45-TC, which was obtained from Caltag Laboratories (Burlingame, CA, USA). In addition, Laser Dye Styryl (LDS751, Molecular Probes, Leiden, The Netherlands) was used for nuclear cell identification.
The CD45 marker was tested in each combination to allow a primary gating of BM cell subsets based on CD45 antigen expression and SSC laser light diffraction as described. 22 Orthogonal SSC was compared with that obtained for mature granulocytes in healthy control peripheral blood specimen processed in the same day. 23 and the subsequent modification of the European Working Group of Clinical Cell Analysis (EWGCCA). 24 The CD34 þ cells were characterized using the combination CD34/CD33/CD45. CD34+ B-cell precursors were excluded basing on CD10 and CD19 staining. Furthermore, myeloid cells were analyzed using various MoAb combinations (CD16/CD33, CD16/CD13, CD16/CD45); CD14 was employed to quantify monocytes and to gate-out these cells from the granulocytes.
Immunophenotypic data were expressed as percentage of cells positive for one or more antigens. Multiparametric data analysis of antibody staining patterns was used to analyze different trends in antigen expression in the various populations. As the panel of antibodies was modified during the study and additional antibodies were used in the analysis of later cases, data with all the antibodies were not available for all 103 patients of the learning cohort.
Samples from three MDS patients were evaluated in order to test the intralaboratory repeatability and reproducibility of specimen preparation, acquisition, and analysis. Briefly, for a single specimen, aliquots were prepared in replicate by four independent investigators, who then analyzed, in a blind manner, each specimen three times.
Statistical analysis
An analysis of variance comparing means between multiple groups was performed to test each numerical parameter for differences between MDS patients and pathologic and healthy controls, and among MDS subgroups according to the WHO classification. A logarithmic transformation was performed to normalize the distribution of the variables. Post-hoc comparisons were carried out using Scheffe's test. Associations between categorical ordinal variables were tested by Fisher's exact test or Pearson's chi-square; associations between ordinal and continuous variables were tested by linear regression models. Discriminant analyses were performed to identify the presence of erythroid and myeloid dysplasia, with the aim of differentiating MDS and pathologic controls, and of classifying, together with flow-cytometric blast percentage, MDS into WHO subgroups: refractory anemia, refractory cytopenia, and refractory anemia with excess blasts.
A repeated-measure analysis of variance was carried out on data obtained from three MDS samples evaluated by four blinded independent investigators, who analyzed each sample three times, in order to estimate the between-investigator (s 2 bi ) and within-investigator (or trial-to-trial) (s 2 wi ) components of variance. All analyses were performed using Statistica 6.0 software (Statsoft Inc., Tulsa, OK, USA) and Microsoft s Excel 2000 (Microsoft Inc., Redmond, Washington, DC, USA).
Results
The learning cohort consisted of 103 MDS patients, 27 patients with hematological disorders sharing clinical features with MDS, and 19 healthy BM donors. MDS were classified as refractory anemia (RA) (21 cases), RA with ringed sideroblasts Flow cytometry immunophenotyping in myelodysplastic syndromes L Malcovati et al (RARS) (15 cases), refractory cytopenia with multilineage dysplasia (RCMD) (14 cases), RCMD with ringed sideroblasts (RCMD-RS) (six cases), refractory anemia with excess blasts 1 (RAEB-1) (14 cases), RAEB-2 (28 cases), MDS with isolated del(5q) (three cases), MDS unclassified (MDS-U) (two cases). Pathological controls included 13 idiopathic or iatrogenic BM hypoplasia, four infective cytopenia, three megaloblastic anemia, four anemia associated with marrow infiltration, and three idiopathic thrombocytopenic purpura.
Flow cytometry analysis of erythroid cells
The erythroid compartment was analyzed and quantified using the CD71/GlyA/LDS751/CD45 combination. A strong correlation was observed between morphological evaluation of nucleated red blood cells and immunophenotypic assessment (r ¼ 0.82, Po0.001), flow cytometry tending to underestimate the value of immature erythroid cells (slope: 0.547, intercept: 5.521). A myeloid to erythroid ratio was calculated through flow cytometry as the ratio between the percentage of CD33 þ cells and of nucleated red cells, which was significantly associated with the results obtained through morphological analysis, flow cytometry resulting in an overestimation of the ratio in comparison with morphology (median value 2.96 vs 1.97, respectively) (r ¼ 0.72, Po0.001; slope: 1.731, intercept: 0.842). Data obtained from the repeated-measure analysis including specimen preparation, acquisition, and analysis by four blinded investigators showed that the between-and the within-investigator components of variance did not affect significantly the results (P ¼ 0.80 and 0.12, respectively).
A significantly higher proportion of immature red cells was noticed in MDS patients than in controls (Po0.001, Table 1 ). A significant correlation was found between the degree of erythroid dysplasia (morphological assessment) and proportion of immature red cells (flow cytometry immunophenotypic evaluation) in MDS patients (r ¼ 0.53, Po0.001).
A quantitative analysis of the GlyA/CD71 pattern showed a lower percentage of GlyA þ CD71 þ nucleated red cells in MDS patients than in healthy controls (P ¼ 0.02) (Figure 1) , with not significant between-and within-investigator variability (P ¼ 0.84 and 0.98, respectively).
Flow cytometry analysis of myeloid cells
Myeloid dysplasia was first analyzed by quantifying the expression of each MoAb on granulocytes and monocytes. With respect to controls, MDS patients showed a lower proportion of CD10 þ granulocytes (Po0.001) and higher proportions of CD56 þ granulocytes (Po0.001). The analysis of variance for repeated measures showed that between-and These results were obtained via a repeated-measure analysis of variance on data from three MDS samples evaluated by four blinded independent investigators, who analyzed each sample three times. c All the variables were log-transformed before the analysis of variance to normalize the distribution. 
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L Malcovati et al within-investigator variances were not significant in both CD10 (P ¼ 0.11 and 0.98, respectively) and CD56 (P ¼ 0.95 and 0.40, respectively) expression analysis. A significant correlation was found between the proportion of both CD10 þ and CD56 þ granulocytes and the degree of myeloid dysplasia as defined by morphological assessment (r ¼ À0.38, Po0.001 and r ¼ 0.39, P ¼ 0.002, respectively). In order to evaluate myeloid maturation, we analyzed the following patterns: CD33 vs CD16, CD45 vs CD16, and CD13 vs CD16. All these patterns were more frequently abnormal in MDS patients than in controls (P from 0.02 to 0.001). For each pattern, we analyzed and quantified the myeloid subpopulations according to different antigenic expression. As shown in Figure 2 , MDS patients showed increased proportions of the more immature immunophenotypic compartments (CD33 þ CD16À, CD45 þ CD16À, CD13 þ CD16À) of myeloid cells and decreased proportions of mature granulocytes
Between-and within-investigator variances were estimated for the CD33 vs CD16 expression analysis. The repeated-measures analysis of variance showed that both these components of the analytical variance did not significantly affect the result (P ¼ 0.94 and 0.95, respectively).
For each of these patterns, we calculated an immature to mature cell ratio. Thus, CD33/CD16, CD45/CD16, and CD13/ CD16 ratios were significantly higher in MDS patients than in controls (P values from 0.02 to 0.001) ( Table 1 ). Significant positive correlations were found between these ratios and the degree of morphological marrow myeloid dysplasia (r values ranging from 0.30 to 0.67, P values from 0.002 to o0.001).
Flow cytometry analysis of CD34 þ cells
The percentages of CD34 þ cells and CD34 þ CD33 þ cells were significantly higher in MDS patients than in controls (P ¼ 0.006 and Po0.001, respectively). Linear regression analysis showed a close relationship between the degree of erythroid and myeloid dysplasia (morphological assessment) and the proportion of CD34 þ cells (r ¼ 0.31, P ¼ 0.001 and r ¼ 0.48, Po0.001, respectively).
A ratio between the CD34 þ CD33 þ and CD34 þ CD33À cells was calculated (Figure 3 ), significantly higher in MDS patients than in controls (Po0.001, Table 1 ), and positively correlated with both erythroid and myeloid dysplasia (r ¼ 0.27, P ¼ 0.006 and r ¼ 0.40, Po0.001, respectively). Repeatedmeasures analysis of variance showed that neither the between-investigator nor the within-investigator components of variance significantly affected the results of CD34 (P ¼ 0.27 and 0.30, respectively) and CD34/CD33 analyses (P ¼ 0.94 and 0.95, respectively). 
Flow cytometry analysis of blast cells
Discriminant analysis: erythroid dysplasia
Discriminant analysis was performed with the aim of distinguishing MDS patients from controls based on flow cytometry estimates that were previously found to be related to erythroid dysplasia. A classification function was obtained as a linear percentage of BM CD34 þ cells, CD34 þ CD33 þ /CD34 þ CD33À cell ratio, nucleated red cell percentage, and GyA/CD71 expression. Antibody combinations used for the analysis of parameters of interest are specified in Table 2 . In order to classify a subject, the function must be evaluated using the patient's values of the selected parameters: the patient will be classified as having MDS if the obtained value is greater than zero or as not having MDS if the value is lower than zero. Table 3 shows the erythroid classification function. Within the MDS group, only patients with definitive morphological evidence of erythroid dysplasia were included in the discriminant analysis. As mentioned previously, the antibody panel evolved during the study, and therefore not all patients were valuable for the discriminant analysis. Consequently, the discriminant function was tailored on a total of 68 subjects, 32 MDS patients and 36 pathologic controls. Of the 32 MDS patients, 30 (93.7%) were correctly classified.
Significant positive correlations were observed between the numerical value of the erythroid classification function and both the degree of the erythroid marrow dysplasia assessed by morphology (r ¼ 0.61, Po0.001), and the IPSS (r ¼ 0.56, P ¼ 0.001). Out of 36 control subjects, 34 (94.4%) were correctly classified. The two false positives were patients with megaloblastic anemia.
In all, 20 MDS patients had isolated macrocytosis or normomacrocytic anemia with not definitive evidence of erythroid dysplasia at the time of diagnosis. In these cases, the diagnosis of MDS was based upon the presence of cytogenetic abnormalities (12 patients) and/or defective in vitro colony formation. In all these cases, the diagnosis of MDS was confirmed by follow-up investigations. These patients were not included in the discriminant analysis: using the erythroid discriminant function, a diagnosis of erythroid dysplasia was formulated in 12 out of 20 of these patients with nondiagnostic erythroid morphology.
Discriminant analysis: myeloid dysplasia
A discriminant function based on percentage of BM CD34 þ cells, myeloid/lymphoid ratio, CD10 and CD56 expression on myeloid cells, and a CD33/CD16 ratio of immature to mature myeloid cells was estimated in order to distinguish MDS patients with myeloid dysplasia from MDS patients without myeloid involvement or controls. Antibody combinations used for the analysis of parameters of interest are shown in Table 2 . All variables were log-transformed to normalize their Flow cytometry analysis of CD34 þ cell subsets: determination of CD34 þ CD33 þ to CD34 þ CD33À cell ratio. The ratio was significantly higher in MDS patients (b) than in normal controls (a). (Table 3) was then integrated with the immunophenotypic blast count, based on the dot-plot CD45/SSC and FSC/SSC, and confirmed with a back-gating technique, to discriminate among refractory cytopenia, RAEB-1, and RAEB-2. A total of 31 MDS patients and 23 controls were included in this analysis. Only two subjects were incorrectly classified using the myeloid discriminant function (6.5%). No false positives were detected among control subjects. Strong positive relationships were found between the value of the myeloid discriminant function and both the degree of morphological myeloid dysplasia (r ¼ 0.79, Po0.001), and the IPSS (r ¼ 0.67, Po0.001).
Prospective validation of the discriminant functions
A prospective study for validating the obtained classification functions was then carried out on a series of 115 consecutive, unselected patients referred to our Institution for mono-or multilineage cytopenia. The definitive diagnosis was of MDS in 69 cases (20 RA, 10 RARS, 10 RCMD, four RCMD-RS, eight RAEB-1, 14 RAEB-2, three MDS unclassified). The remaining 46 patients had idiopathic BM aplasia (four cases), iatrogenic BM hypoplasia (14 cases), anemia associated with marrow infiltration (15 cases), transient pancytopenia (one case), megaloblastic anemia (five cases), iron deficiency anemia (three cases), and anemia of chronic inflammation or associated with liver disease (four cases). A correct diagnosis was obtained in 60 out of 69 MDS cases (87%). Six patients with refractory anemia (two with ringed sideroblasts) had a negative erythroid function. Two patients showed a very low value of the erythroid function (Figure 4 ), one affected with a MDS with marrow fibrosis, the other one with a hypoplastic MDS. One patient with RCMD with a highly hypocellular BM aspirate had a negative result in both the erythroid and myeloid functions. Two patients with MDS-U and a mild myeloid dysplasia had a negative myeloid function. Seven MDS patients had an incorrect WHO subgroup assignment. No false-positive cases were noticed among 46 pathologic controls (Figure 4) . In this cohort, a definite morphologic diagnosis of MDS, based upon marrow aspirate concurrently used for cytometry, was obtained in 44 out of 69 MDS patients (64%). Among patients with a conclusive morphology, a flow-cytometric diagnosis of MDS was formulated in 41 of 44 cases (93%), while in patients with an indeterminate morphology flow-cytometric analysis allowed a diagnosis in 19 of 25 cases (76%).
Discussion
In this study, we used a simple form of flow cytometry immunophenotyping that provides percentages of positive cells. As previously found by other investigators, 8, 9, 11 no single immunophenotypic parameter proved able to discriminate accurately between MDS and other pathological conditions. Therefore, we performed discriminant analyses using several immunophenotypic parameters: this allowed us to define classification functions that proved useful in distinguishing MDS from other conditions both in the learning and the testing cohorts. In addition, these functions provided a reliable evaluation of erythroid and myeloid dysplasia in MDS patients.
A major problem in immunophenotypic analysis of MDS is evaluation of the erythroid dysplasia because of limited availability of antibodies specific for this lineage. In our study, we used a lyse-no wash technique with the aim of simplifying the approach and of facilitating its inclusion in the work-up of MDS patients, though this technique could potentially affect nucleated red cell estimate. A regression analysis of cytometric vs morphological analysis of nucleated red cell showed that an underestimation of the immature erythroid cells is obtained by Flow cytometry immunophenotyping in myelodysplastic syndromes L Malcovati et al flow cytometry, resulting in a higher myeloid to erythroid ratio with respect to morphological analysis. However, a strong linear correlation between morphological and immunophenotypic evaluation of nucleated red cells was found, and flowcytometric analysis was demonstrated to be repeatable and reproducible, without significant differences among investigators who processed and repeatedly analyzed samples in a blind manner. Dys-synchronous expression of CD71 vs glycophorin A on red cell precursors, a finding previously reported by others, 8 was the only consistent erythroid abnormality in our study.
By contrast, various immunophenotypic abnormalities of myeloid cells have been previously recognized through the use of different MoAbs. 8, 11, 12 In this study, MDS patients showed increased proportions of myeloid cells in the more immature immunophenotypic compartments and decreased proportions of mature granulocytes. Thus, we defined a ratio of immature to mature cells, which was markedly increased in MDS patients and significantly correlated with the degree of morphological myeloid dysplasia.
As far as CD34 þ cells are concerned, as previously reported by Del Cañ izo et al, 11 we found a significantly higher percentage of CD34 þ hematopoietic progenitor cells. The ratio between the CD34 þ CD33 þ and CD34 þ CD33À cells was significantly higher in the MDS group than in the controls.
The immunophenotypic analysis of hematopoietic compartments allowed us to estimate discriminant functions to differentiate between patients with MDS and those with other pathologies, including disorders similar to MDS, such as megaloblastic anemia and BM hypoplasia. A crucial point in immunophenotype in MDS is blast count. In our study, we observed a strong correlation between the proportion of blast cells estimated by morphology and the proportion of cells into the blast gating. A significant correlation between the proportion of CD34-positive cells analyzed by a single-platform standardized method and the percentage of BM blasts evaluated by cytometry was also noticed. Finally, in our experience blast count was not significantly affected by between-and withininvestigator variability. Therefore, we decided to integrate erythroid and myeloid discriminant functions with blast count obtained on the dot-plot CD45/SSC in order to classify MDS into WHO subgroups.
Our immunophenotypic approach allowed us to correctly classify more than 90% of MDS with definitive morphological marrow dysplasia in the learning cohort and was validated in the prospective analysis of a testing cohort of patients. Moreover, flow-cytometric analysis has been demonstrated to be sensitive also in a high proportion of cases with a nondiagnostic morphology. This seems to suggest that variables related to sample quality, such as peripheral blood contamination or hypocellularity, are less significant in immunophenotypic analysis than in morphological evaluation. Finally, the quantitative evaluation provided by the discriminant functions reflected the severity of marrow dysplasia.
In conclusion, an accurate flow cytometry evaluation of marrow dysplasia was achieved in this study with a panel of eight MoAbs, including MoAb against CD45, CD10, CD16, CD33, CD34, CD56, CD71, and GlyA-PE. This immunophenotypic analysis showed intralaboratory repeatability and reproducibility, and can be performed at a reasonable cost. Both these features make this approach potentially useful in the work-up of patients with MDS. The classification functions developed by us can be easily inserted in a Microsoft s Excel sheet, so that their use by clinicians is extremely simple. Although interlaboratory variability has been demonstrated to be a problematical issue in flow-cytometric immunophenotyping, such an approach might be a potentially useful tool for multicenter cytometric studies aimed at defining prognostic factors and predictors of response in MDSs. 25, 26 
